GlassScriptPhysician profile
Hannah Song
NPI 1710476932
$1,114.85
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $148 · 2023: $640 · 2024: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.01 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $381.90 | 2022-2024 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $282.90 | 2022-2024 | Tremfya |
| Lilly USA, LLC | $107.37 | 2022-2024 | Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $59.50 | 2024 | Dupixent |
| Galderma Laboratories, L.P. | $52.14 | 2023 | |
| Ucb, INC. | $50.18 | 2023-2024 | Bimzelx, Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.30 | 2023 | Spevigo |
| Sun Pharmaceutical Industries INC. | $30.39 | 2023 | Ilumya, Odomzo, Blu-U |
| Arcutis Biotherapeutics, INC. | $29.11 | 2024 | Zoryve |
| Tactile Systems Technology INC | $25.20 | 2024 | Flexitouch Plus, Entre Plus |
| Genzyme Corporation | $24.68 | 2024 | |
| Dermavant Sciences, INC. | $20.71 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.